Vivos Therapeutics to Participate in Upcoming Investor Conferences

HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will participate in the following upcoming conferences.

• Q1 Virtual Investor Summit. Vivos’ presentation is scheduled for Tuesday, March 8, 2022, at 4:15 pm Eastern Time. Investors interested in joining the Vivos presentation can register at the link below:
  https://us06web.zoom.us/webinar/register/WN_K-7zUZWFQ5iR4Y6VX4QC-w

• 34th Annual ROTH Conference being held virtually and in-person in Dana Point, CA from March 13-15, 2022. CEO Kirk Huntsman will conduct meetings with investors and participate in a fireside chat on Tuesday, March 15, 2022, at 8:30 am Pacific Time (11:30 am Eastern Time). Investors interested in joining the Vivos presentation can register at the link below:
  https://us01.z.antigena.com/l/iZHj5crNT77vHsEO9pBf68fIvkTceadMLVxHXn4B-ING7OKGtJPxOvJ~x0X6~x2RA33NOuMci-00w40gej7Pzrrhe59C~EkKSk1yUc_2HRbYnMTXhXIwYrZY5y1aNTIkGL5T7FaBzzIf5-i-MI3iyCrKmIcP9UaqPqz_KOF

Institutional investors interested in one-on-one meetings with Vivos management at the ROTH Conference should contact their ROTH Capital institutional sales representative.

Replays of these presentations will be available on Vivos’ website at: https://vivos.com/investor-relations.

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment methods for treating patients with dentofacial abnormalities and / or mild to moderate sleep apnea (OSA) and snoring. The Vivos Method represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution. The Vivos Method has proven to be effective in approximately 25,000 patients treated worldwide by more than 1,450 trained dentists.

Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos Method.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements
This press release, the presentations referred to herein and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim”, “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the results of the Company’s sales, marketing, research and development and regulatory initiatives) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Vivos Investor Relations Contact:
Julie Gannon
Investor Relations Officer
(303) 859-3847
jgannon@vivoslife.com

Vivos Media Relations Contact:
Francesca DeMauro / Jenny Robles
KCSA Strategic Communications
(917) 880-9771 / (212) 896-1231
fdemauro@kcsa.com / jrobles@kcsa.com